Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
SGQ 0.300 +0.0% AMCO 0.250 +0.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.910 +0.0% SMY 0.235 +0.0% SAG 1.02 +0.0% NTH 0.165 +0.0% PEMC 0.045 +0.0% NAR 0.180 +0.0% ARG 6.99 +0.0% VMXX 0.970 +0.0% ABRA 14.01 +0.0% LAF 1.63 +0.0% AMX 4.14 +0.0% SGQ 0.300 +0.0% AMCO 0.250 +0.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.910 +0.0% SMY 0.235 +0.0% SAG 1.02 +0.0% NTH 0.165 +0.0% PEMC 0.045 +0.0% NAR 0.180 +0.0% ARG 6.99 +0.0% VMXX 0.970 +0.0% ABRA 14.01 +0.0% LAF 1.63 +0.0% AMX 4.14 +0.0%

Healthcare

Page 40
  1. Mar 31, 2026 · 12:40 · AQS · Routine −

    Aequus Offloads Final Asset for Half-Million as NEX Transfer Signals Corporate Wind-Down

    Aequus Announces Completion of Previously Announced Sale of ZIMED(R) PF

    01
  2. Mar 31, 2026 · 10:20 · INNO · Routine +

    [Value]

    Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest

    02
  3. Mar 31, 2026 · 08:50 · OTC · Neutral

    Ocumetics Pivots to Partner Outreach as Clinical Data Meets Industry Scrutiny

    Ocumetics Technology Corp. Achieves Breakthrough in Next-Generation Accommodating Intraocular Lens Design

    03
  4. Mar 31, 2026 · 08:30 · MVMD · Routine +

    MVMD Secures $2M Lifeline at Steep Discount as Warrant Strike Aligns with Recent Price Spike

    Mountain Valley MD Announces Strategic Non-Brokered Private Placement of Units and Concurrent Shares for Debt Transaction

    04
  5. Mar 31, 2026 · 07:45 · NGEN · Routine +

    Clinical Validation Confirmed, Capital Runway Tightens Ahead of Phase 3 Pivot

    NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

    05
  6. Mar 31, 2026 · 07:30 · CTX · Routine +

    Crescita Locks $0.80 Buyout as Q4 Earnings Validate Manufacturing Pivot

    Crescita Reports Q4 and Fiscal 2025 Results

    06
  7. Mar 31, 2026 · 07:01 · FNDX · Neutral

    FendX Pivots to Liquid Coatings and Settles Debt in Shares as Stock Tests Lows

    FendX Provides Corporate Update

    07
  8. Mar 31, 2026 · 07:00 · VITA · Material −

    Vitalist Bets on Medical AI Acquisition While Cash Reserves Dwindle and Debt Looms

    Vitalist Inc. Expands Global Wearable Footprint via Acquisition of Somatix, Adding Medical Grade AI and Remote Patient Monitoring to VitalOS(TM)

    08
  9. Mar 31, 2026 · 07:00 · TELO · Neutral

    Telo Genomics Swaps Founder for Veteran CEO as Cash Burn Outpaces Clinical Validation

    Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

    09
  10. Mar 31, 2026 · 06:31 · THRM · Routine +

    [Value]

    Therma Bright Signs New Strategic Customer, Horizon Health, Currently Selling over 35,000 Compression Products Annually

    10
  11. Mar 31, 2026 · 06:31 · CHS · Routine +

    CHS Pitches $20M Pipeline and AI Upgrades as Capital Extension Looms

    Comprehensive Healthcare Systems Provides Business Development Update Highlighting Expanding Pipeline and Operational Enhancements

    11
  12. Mar 31, 2026 · 03:00 · INNO · Routine +

    Insider Debt Bridges Runway as Core Revenue Slips Ahead of Uncertain U.S. Uplisting

    Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M

    12
  13. Mar 30, 2026 · 18:07 · QNTM · Routine +

    Court Clears Path for $700M Spoofing Suit, But Cash Burn and Clinical Execution Remain the Real Hurdles

    Quantum Biopharma signs LOI for phase 2 MS trial

    13
  14. Mar 30, 2026 · 16:59 · MRVL

    Marvel obtains Alberta funding for MB-204 phase I

    Marvel obtains Alberta funding for MB-204 phase I

    14
← Newer Older →